Eli Lilly and Company, UnitedHealth Group, Tempus AI, Novo Nordisk A/S, Hims & Hers Health, Gilead Sciences, and Walmart are the seven Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies operating in the healthcare sector, including pharmaceuticals, biotechnology, medical device manufacturers and health-care service providers. Investors buy these equities to gain exposure to innovations in drug development, medical technology and patient care. Their market performance is often driven by factors such as regulatory approvals, clinical trial results and industry demand trends. These companies had the highest dollar trading volume of any Medical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of NYSE LLY traded down $4.07 during trading hours on Friday, hitting $636.79. 8,323,236 shares of the company traded hands, compared to its average volume of 3,987,886. The company's 50 day moving average price is $776.36 and its 200 day moving average price is $799.60. The stock has a market capitalization of $603.51 billion, a price-to-earnings ratio of 51.64, a price-to-earnings-growth ratio of 1.06 and a beta of 0.44. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $972.53.
Read Our Latest Research Report on LLY
UnitedHealth Group (UNH)
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.
UnitedHealth Group stock traded up $6.33 during trading hours on Friday, hitting $251.00. The company had a trading volume of 5,460,339 shares, compared to its average volume of 12,070,221. The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.85 and a current ratio of 0.85. The company has a 50-day moving average price of $292.78 and a two-hundred day moving average price of $408.71. The firm has a market cap of $227.69 billion, a P/E ratio of 10.84, a P/E/G ratio of 1.59 and a beta of 0.43. UnitedHealth Group has a 1 year low of $234.60 and a 1 year high of $630.73.
Read Our Latest Research Report on UNH
Tempus AI (TEM)
Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
NASDAQ TEM traded up $1.91 during midday trading on Friday, hitting $60.65. 22,421,954 shares of the company traded hands, compared to its average volume of 12,434,220. The company's 50-day simple moving average is $62.34 and its 200-day simple moving average is $57.91. Tempus AI has a 52 week low of $31.36 and a 52 week high of $91.45. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.71 and a quick ratio of 1.56. The company has a market cap of $10.50 billion, a PE ratio of -7.74 and a beta of 4.98.
Read Our Latest Research Report on TEM
Novo Nordisk A/S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Shares of NVO traded up $2.35 during mid-day trading on Friday, hitting $51.11. 16,463,050 shares of the company traded hands, compared to its average volume of 11,286,497. Novo Nordisk A/S has a 1-year low of $45.05 and a 1-year high of $139.74. The business has a 50 day moving average of $67.55 and a 200 day moving average of $71.81. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $228.22 billion, a PE ratio of 14.03, a price-to-earnings-growth ratio of 1.37 and a beta of 0.63.
Read Our Latest Research Report on NVO
Hims & Hers Health (HIMS)
Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
HIMS traded up $0.70 during trading on Friday, reaching $51.75. 15,062,040 shares of the company's stock were exchanged, compared to its average volume of 34,300,070. The company's fifty day simple moving average is $53.76 and its 200-day simple moving average is $44.79. The stock has a market capitalization of $11.58 billion, a P/E ratio of 64.19, a price-to-earnings-growth ratio of 2.16 and a beta of 2.08. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 1.32. Hims & Hers Health has a 1 year low of $13.47 and a 1 year high of $72.98.
Read Our Latest Research Report on HIMS
Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
NASDAQ GILD traded up $9.82 during mid-day trading on Friday, reaching $120.10. 6,046,021 shares of the stock were exchanged, compared to its average volume of 8,376,022. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. Gilead Sciences has a 1 year low of $72.43 and a 1 year high of $121.38. The business's 50 day moving average is $110.75 and its 200-day moving average is $107.25. The company has a market capitalization of $149.39 billion, a P/E ratio of 25.24, a P/E/G ratio of 0.70 and a beta of 0.33.
Read Our Latest Research Report on GILD
Walmart (WMT)
Walmart Inc. engages in the operation of retail, wholesale, other units, and eCommerce worldwide. The company operates through three segments: Walmart U.S., Walmart International, and Sam's Club. It operates supercenters, supermarkets, hypermarkets, warehouse clubs, cash and carry stores, and discount stores under Walmart and Walmart Neighborhood Market brands; membership-only warehouse clubs; ecommerce websites, such as walmart.com.mx, walmart.ca, flipkart.com, PhonePe and other sites; and mobile commerce applications.
WMT traded up $1.30 during midday trading on Friday, hitting $104.42. 6,058,934 shares of the company traded hands, compared to its average volume of 19,047,502. The company has a current ratio of 0.78, a quick ratio of 0.22 and a debt-to-equity ratio of 0.47. Walmart has a 52-week low of $67.14 and a 52-week high of $105.30. The company has a market capitalization of $833.31 billion, a price-to-earnings ratio of 44.56, a PEG ratio of 4.97 and a beta of 0.66. The business has a 50 day simple moving average of $97.20 and a two-hundred day simple moving average of $95.29.
Read Our Latest Research Report on WMT
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
